| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2007-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c98aaebebfc912853930a97d7a13ff23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_045b8818c62817bc420a19784de9d367
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcf05d4f98c38e4cd5dfcad086cb2828
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85ee5888edc7339a7056afb8be78cdfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d561f50cb6477665350f4a16b40ad3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_052c3681664044c86921e4d956f2ac14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c77936fce552d2606835f91c46d9f71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da2b121865a29c8ddfe663fdc15f1df1 |
| publicationDate |
2008-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008095765-A1 |
| titleOfInvention |
IL-5R-specific antibody composition |
| abstract |
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human interleukin-5 receptor α chain and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10260089-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013066780-A3 |
| priorityDate |
2003-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |